Eli Scher retweeted
Not often do we publish 2 back to back guidelines on #NasopharyngealCarcinoma in @JCO_ASCO
Was a pleasure leading this monumental effort with @BrigetteMa2 @ASCO CSCO 💪🏻💪🏻💪🏻
Treatment of Stage IB to III Nasopharyngeal Carcinoma: CSCO-ASCO Guideline Update | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JCO…
Eli Scher retweeted
🫁🌶️ SPICE-ing up lung SBRT
Intentional tumor 🔥hotspot (PTV Dmax ≥120%) vs <120% in VMAT SBRT for early-stage NSCLC
3-year local recurrence rates:
🔥0% with ≥120% hotspot
🧊8-9% with <120% hotspot
📚 Not a novel concept. Prior work has suggested that higher intratumoral dose improves local control!
✅ What this study contributes is additional clinical evidence, plus a practical planning strategy (SPICE: Stereotactic Planning with Intentional Central Escalation).
⚠️ No PFS or OS advantage seen.
🎯Take-home: Another data point supporting intentional hotspot escalation in lung SBRT, rather than proof of a brand-new concept
@ASTRO_org
advancesradonc.org/article/S…
Eli Scher retweeted
🧵 Excited to share our multicenter, prospective phase 2 trial of proton re-irradiation for people with recurrent head & neck cancer, now in @JournalCancer
Grateful to Dr @IMRTLee @xrtGenomics @DrPaulRomesser and team for the opportunity to write 🙏
🔗 acsjournals.onlinelibrary.wi…
Eli Scher retweeted
Now in @JAMAOnc:
We report 5y outcomes post 30 Gy elective RT (total 70 Gy CCRT) for 276 pts w/ HPV-related OPC #hncsm at @MSKCancerCenter #radonc
LRC 97.0%
OS 90.8%
PFS 85.9%
DMFS 91.2%
@imrtlee @xrtGenomics @seanmmcbride @CJTsaiMDPhD @EChrisDee
👉 shorturl.at/liqpP
Eli Scher retweeted
OPTIMAL is asking whether selected oral cavity cancer responders can skip postoperative RT. Still awaiting primary endpoint, 2y EFS (not reported just yet)
Randomized phase II, 116 pts with resectable locally advanced oral cavity SCC, 1:1, stratified by stage III vs IVA:
Surgery→ standard postoperative RT/CRT
vs.
Tislelizumab + nab-paclitaxel + cisplatin x3c→ surgery→ response-adapted adjuvant treatment.
Neoadjuvant doses: tislelizumab 200 mg, nab-paclitaxel 260 mg/m², cisplatin 75 mg/m² q3w. Pts with "aMPR" and no positive margins/ENE received tislelizumab x6c without RT. Other operated pts received postoperative RT/CRT. aMPR isn't defined in the report; the registry uses MPR.
📌 Experimental ORR 81% (47/58). Among 55 pts who underwent surgery, pCR 45.5% (25/55).
G3+ TRAEs 36.2→ 25.9% (control→ experimental), described as mainly related to RT and surgery.
At the 6 Sep 2026 cutoff, control had 19 EFS events, including 8 deaths. The reported neoadjuvant-plus-RT subgroup had 9 EFS events: 3 PD during neoadjuvant treatment, 5 relapses, and "1 died due to radiotherapy complications, 3 deaths" as written. I'm not sure how the death counts reconcile. The RT-free subgroup had 2 EFS events and 0 deaths.
The primary endpoint, 2y EFS, is NOT reported. EFS is immature, with no rates or HR and no MFU given. Those raw counts can't answer the RT question: the RT-free pts were selected responders without positive margins/ENE, not a separately randomized group, and the subgroup denominators aren't given.
I'd also want the control-arm RT/CRT details and RT dose/fx, which aren't reported. Interesting response-adapted strategy, with substantial pathologic response, but this doesn't establish that we can safely omit RT.
cslide.ctimeetingtech.com/es…
#radonc #ESMO26 #HeadAndNeckCancer
OPTIMAL: pCR 45.5% (25/55 operated) after neoadjuvant tislelizumab + chemo in resectable oral cancer.
Primary 2-year EFS success remains unproven. RT omission was response-selected.
What evidence would make you omit RT?
@hf_kao @myESMO @OncoAlert @OncoDaily #ESMO26
Eli Scher retweeted
14.8% invasive local recurrence at 5y after BCS alone in TOP-1.
Age 70+, small low-grade ER+ tumors, no RT or ET.
Most recurrences were salvaged, but that is still more treatment. I'd be cautious about routinely omitting both.
#ESMO26 #radonc
cslide.ctimeetingtech.com/es…
Eli Scher retweeted
LINACS is online!
What? Living Systematic Review on Safety of Stereotactic RT ⚡️+ Novel Anticancer Drug 💊
Published url.de.m.mimecastprotect.com…
Online Database: linacs.net
Housed in @ESTRO_RT @EORTC Oligocare consortium
Updated every 6 mo 🔄
🧵
Eli Scher retweeted
With the shift towards Ind Chemo in #NasopharyngealCarcinoma #NPC many unanswered questions remains:
We highlight them in this month's RedJ editorial @ASTRO_org @sueyom @lachiemcd
1. Optimal no of cycles
2. Utilising on-treatment response
3. How do we manage poor responders to IC - midway switch or stop at 2
4. What about non-endemic and EBV- NPC
Free link below for 50 days! ⬇️
sciencedirect.com/science/ar…
Eli Scher retweeted
Re-irradiation in H&N cancer is finally getting a framework.
The new ReCOG-ESTRO-ASTRO consensus highlights some important nuances:
Eli Scher retweeted
Major congrats to @imrtlee and @xrtGenomics (amongst others) on this wonderful news! The Ph3 is enrolling rapidly. This RCT has more practice changing potential than any in which I've had the good fortune to participate. #radonc #hnscc #medtwitter
onclive.com/view/fda-grants-…
Eli Scher retweeted
Very thoughtful commentary from the stellar Red Journal H&N editors!
redjournal.org/article/S0360…
Eli Scher retweeted
Question born in a clinic. 74 patients with HNSCC undergoing CTRT. Two blinded oncologists grading toxicities.
Now in Red Journal
Mucositis, ≥G2 κ: 0.23–0.41 | 91.9% vs 70.2%,
Assessor = hidden covariate in every tox endpoint
doi.org/rmn6
@IJROBP @RadOncTMC
This is exactly what we found: post-op PET/CT sim detected early recurrence in 16.5% of resected OSCC pts vs 3.3% with CT alone (n=391, aOR 7.9). The highest risk was in the ECE/SM+ group, but the DFS/OS benefit was in intermediate-risk pts (HR 0.46). You can't unsee it
I now routinely perform PET-CT simulation for high-risk postop H&N cases and not uncommonly find residual (or progressive) FDG-avid disease.
It makes me question whether the postop RT literature on intensification needs to be re-examined. How much is the benefit of chemotherapy, or prompt RT start, or even nivolumab, related to its efficacy in managing actual gross disease versus microscopic residual.
Eli Scher retweeted
1/2
📢Terrific, impactful work in @Annals_Oncology by @HugoAerts @Dr_RayMak & Team on the potential importance of sparing the thymus when giving 🫁 #radiotherapy, on the heels of their recent @Nature papers🔥🔥🔥
⬇️ Links below
Eli Scher retweeted
I now routinely perform PET-CT simulation for high-risk postop H&N cases and not uncommonly find residual (or progressive) FDG-avid disease.
It makes me question whether the postop RT literature on intensification needs to be re-examined. How much is the benefit of chemotherapy, or prompt RT start, or even nivolumab, related to its efficacy in managing actual gross disease versus microscopic residual.
Eli Scher retweeted
The identification of the tubarial gland is a really cool story, though I am doubtful that TG-sparing radiotherapy will make a meaningful difference to patient-reported xerostomia.
Sparing the contralateral TG should already effectively be part of standard practice for ipsilateral-only nodal disease, and the ipsilateral TG will receive dose from elective treatment of the RP nodes.
We recently looked at patient-reported outcomes as a function of tubarial gland dose and could not find a significant relationship (and this included patients treated without ENI, so there was a truly variable dose to the TG):
sciencedirect.com/science/ar…
A new organ has been found behind your nose.
For centuries, every anatomy textbook swore there were only three pairs of major salivary glands. Turns out the books were wrong, and the missing ones were hiding in plain sight.
In 2020, Dutch researchers scanning head-and-neck cancer patients with a cutting-edge PET/CT technique (PSMA PET-CT) noticed an unexpected glow deep in the nasopharynx, right where the nasal cavity drains into the throat. No textbook had ever marked a salivary gland there.
They double-checked: 100 consecutive patients → same structure in every single one. Then they dissected two fresh cadavers and there they were: a previously unknown pair of macroscopic salivary glands, roughly 3.9 cm long, draped over the tubarium (the cartilage of the Eustachian tube). The team named them the tubarial glands.
Their job? Keep the upper throat and the back of the nose moist during talking, swallowing, and breathing, an area that gets painfully dry after radiation.
Here’s why this matters: radiation oncologists had never been told to spare this spot. The researchers re-analyzed treatment plans from 723 patients and found the more radiation the tubarial region received, the worse the toxicity, more trouble swallowing, thicker saliva, constant dry mouth.
A simple anatomical blind spot had been quietly worsening outcomes for years.
Now that we know these glands exist, new radiation protocols can shield them, giving thousands of head-and-neck cancer patients an easier road to recovery.
[Valstar, de Bakker, et al., “Discovery of the tubarial salivary glands: a new organ at risk in radiotherapy for head and neck cancer,” Radiotherapy and Oncology 2021, DOI: 10.1016/j.radonc.2020.09.034]
Eli Scher retweeted
Very cool case! 90 yo nursing home-bound gentleman with early-stage larynx cancer.
Treated with 5 fractions and tolerated with minimal acute side effects (mild fatigue and dysphonia) and no longer-term sequelae thus far (7 months later).
Left, today; right, pre-treatment.










































